1. The Expression and Prognostic Value of Cancer Stem Cell Markers, NRF2, and Its Target Genes in TAE/TACE-Treated Hepatocellular Carcinoma. Tseeleesuren D, Hsiao HH, Kant R, Huang YC, Tu HP, Lai CC, Huang SF, Yen CH. Medicina (Kaunas). 2022 Feb 1;58(2):212.
2. The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan. Du JS, Kuo YC, Shi HY, Wang MC, Wang LY, Chuang TM, Ke YL, Yeh TJ, Gau YC, Wang HC, Cho SF, Hsiao SY, Liu YC, Hsu CM, Hsiao HH*. J Pers Med. 2022 Jan 19;12(2):130.
3. Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy. Miyamoto T, Sanford D, Tomuleasa C, Hsiao HH, Olivera LJE, Enjeti AK, Gimenez Conca A, Castillo TBD, Girshova L, Martelli MP, Guvenc B, Delgado A, Duan Y, Garbayo Guijarro B, Llamas C, Lee JH. Leuk Lymphoma. 2022 Feb 11:1-11
4. Is it reasonable for the use of Rh-ee blood? A hospital-based survey from a southern medical center in Taiwan. Hsiao HH*, Yeh CJ, Ting SC, Chuang TM, Ke YL, Yeh TJ, Gau YC, Du JS, Hsiao CE, Wang HC, Cho SF, Hsu CM, Liu YC. Kaohsiung J Med Sci. 2022 Jan;38(1):65-69.
5. Patient with eosinophilic dermatosis of myeloproliferative disease presenting with generalized erythematous plaques - Response to Ruxolitinib. Sun Y, Hsiao HH*, Lan CE. Australas J Dermatol. 2021 Nov;62(4):e613-e615.
6. Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Liu YC, Hsu CM, Hsiao SY, Hsiao HH*. J Pers Med. 2021 Oct 28;11(11):1108.
7. Progression Risk Score Estimation Based on Immunostaining Data in Oral Cancer Using Unsupervised Hierarchical Clustering Analysis: A Retrospective Study in Taiwan. Wang HC, Chan LP, Wu CC, Hsiao HH, Liu YC, Cho SF, Du JS, Liu TC, Yang CH, Pan MR, Moi SH. J Pers Med. 2021 Sep 13;11(9):908
8. Effect of Tumor Microenvironment and Angiogenesis on Clinical Outcomes of Primary Central Nervous System Lymphoma. Wang HC, Hsiao HH, Du JS, Cho SF, Yeh TJ, Gau YC, Liu YC, Moi SH. Biomed Res Int. 2021 Sep 30;2021:3291762
9. Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study. Chuang TM, Liu YC, Hsiao HH, Wang HC, Du JS, Yeh TJ, Gau YC, Ke YL, Yang CI, Lee CP, Hsu CM, Cho SF. Nutrients. 2021 Sep 17;13(9):3243.
10. Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection. Tsai YF, Liu YC, Yang CI, Chuang TM, Ke YL, Yeh TJ, Gau YC, Du JS, Wang HC, Cho SF, Hsu CM, Wu PF, Huang CI, Huang CF, Yu ML, Dai CY, Hsiao HH*. J Pers Med. 2021 Aug 27;11(9):844.
11. A rare patient with primary endogenous Aspergillus endophthalmitis. Chiu YY, Chen YH, Hsiao HH, Du JS. J Microbiol Immunol Infect. 2021 Jun;54(3):538- 539.
12. Effect of Oversulfation on the Composition, Structure, and In Vitro Anti-Lung Cancer Activity of Fucoidans Extracted from Sargassum aquifolium. Hsiao HH, Wu TC, Tsai YH, Kuo CH, Huang RH, Hong YH, Huang CY. Mar Drugs. 2021 Apr 12;19(4):215.
13. Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment. Tsai YF, Hsu CM, Hsiao HH*. J Pers Med. 2021 Apr 2;11(4):267.
14. Identification of Beilschmiedia tsangii Root Extract as a Liver Cancer Cell-Normal Keratinocyte Dual-Selective NRF2 Regulator. Chen YS, Chang HS, Hsiao HH, Chen YF, Kuo YP, Yen FL, Yen CH. Antioxidants (Basel). 2021 Apr 1;10(4):544.
15. A tip of the iceberg: Disseminated plasmablastic lymphoma, diagnosed from a local oral lesion. Ke YL, Hsiao HH, Cho SF, Wu CC. Kaohsiung J Med Sci. 2021 Apr;37(4):346-347
16. Management of Myeloma Bone Lesions.Du JS, Yen CH, Hsu CM, Hsiao HH*. Int J Mol Sci. 2021 Mar 25;22(7):3389.
17. Cytomegalovirus colitis with presentation of hemorrhagic colitis in chronic myeloid leukemia during dasatinib therapy. Chuang TM, Hsu CM, Liang PI, Hsiao HH*. J Formos Med Assoc. 2021 Apr;120(4):1155-1157.
18. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia. Tsai HJ, Hsiao HH, Hsu YT, Liu YC, Kao HW, Liu TC, Cho SF, Feng X, Johnston A, Bomalaski JS, Kuo MC, Chen TY. Cancer Med. 2021 Mar 30.
19. A pilot study: effectiveness of local injection of autologous platelet-rich plasma in treating women with stress urinary incontinence. Long CY, Lin KL, Shen CR, Ker CR, Liu YY, Loo ZX, Hsiao HH, Lee YC.Sci Rep. 2021 Jan 15;11(1):1584.
20. A rare patient with primary endogenous Aspergillus endophthalmitis. Chiu YY, Chen YH, Hsiao HH, Du JS.J Microbiol Immunol Infect. 2021 Jan 6:S1684-1182(21)00012-8.
21. A Phase 1 Study Evaluating Safety and Tolerability of Navitoclax Monotherapy in Japanese Patients with Myeloproliferative Neoplasms H Shibayama, H Tanaka, SP Yeh, HH Hsiao, S Nuthalapati, K Ono, ...Blood 2020, 136, 15-16.
22. Successful eradication of HCV by short-course DAAs in HCV-Positive donor to HCV-Negative recipient during Haplo-HSCT. Gau YC, Hsiao HH*, Huang JF, Yu ML.J Formos Med Assoc. 2020 Nov;119(11): 1717- 1718.
23. Consistent administration of cetuximab is associated with favorable outcomes in recurrent/metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area: a retrospective observational study. Wang HC, Liu PL, Lo PC, Chang YT, Chan LP, Yeh TJ, Hsiao HH, Cho SF. PeerJ. 2020 Sep 10;8:e9862.
24. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2. Yen CH, Hsu CM, Hsiao SY, Hsiao HH*. Int J Mol Sci. 2020 Sep 14;21(18):6723.
25. A tip of the iceberg: Disseminated plasmablastic lymphoma, diagnosed from a local oral lesion. Ke YL, Hsiao HH*, Cho SF, Wu CC. Kaohsiung J Med Sci. 2021 Apr;37(4):346-347.
26. Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases. Shabangu CS, Huang JF, Hsiao HH, Yu ML, Chuang WL, Wang SC. Int J Mol Sci. 2020 May 25;21(10):3732.
27. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice. Kant R, Lu CK, Nguyen HM, Hsiao HH, Chen CJ, Hsiao HP, Lin KJ, Fang CC, Yen CH. Biomed Pharmacother. 2020 Jun 15;129:110348
28. Case report of coexistence of myeloproliferative neoplasms and multiple myeloma. Gau YC, Hsiao HH*, Liu YC, Yeh TJ.Kaohsiung J Med Sci. 2020 Jun;36(6):469-470
29. Calreticulin Mutation Survey by High Resolution Melting Method Associated with Unique Presentations in Essential Thrombocythemic Patients. Liu YC, Lee CP, Yeh TJ, Gau YC, Hsieh CY, Ke YL, Du JS, Lin MH, Wang HC, Tang SH, Cho SF, Hsiao CE, Hsu JF, Hsiao SY, Hsu CM, Hsiao HH*. Mediterr J Hematol Infect Dis. 2020 May 1;12(1):e2020022.
30. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS, Shan YS, Chen LT. Eur J Cancer. 2020 Jan;124:123-130
31. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study. Tsai YF, Yang CI, Du JS, Lin MH, Tang SH, Wang HC, Cho SF, Liu YC, Su YC, Dai CY, Hsiao HH*. Peer J. 2019 Sep 9;7:e7481.
32. Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma. Yeh TJ, Yeh CJ, Liu YC, Hsiao HH*.Transfusion. 2019 Aug;59(8):2751-2752.
33. Anti-tuberculosis agents may be associated with myelodysplastic syndromes. Wu DW, Yang CJ, Tsai JH, Hsiao HH*. Kaohsiung J Med Sci. 2019 Oct;35(10):651-652.
34. Promising effects of pazopanib with radiation on an advanced prostate leiomyosarcoma after failure of systemic chemotherapy. Lin MH, Hsiao HH*. Kaohsiung J Med Sci. 2019 May;35(5):317-318
35. A case of recurrent angiosarcoma with isolated bone marrow metastasis presented as acute disseminated intravascular coagulation. Du JS, Lin CH, Wang HC, Hsiao HH*. Kaohsiung J Med Sci. 2019 Apr;35(4): 244-245
36. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma. Yen CH, Hsiao HH*. Int J Mol Sci. 2018 Nov 7;19(11).
37. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan. Tsai YF, Huang WC, Cho SF, Hsiao HH, Liu YC, Lin SF, Liu TC, Chang CS. Medicine (Baltimore). 2018 Jun;97(26):e11322
38. 1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression. Tseeleesuren D, Kant R, Yen CH, Hsiao HH*, Chen YA. Front Pharmacol. 2018 Feb 2;9:65.
39. Stem cell transplantation for T-cell lymphomas in Taiwan. Bone Marrow Transplant. Hsu YT, Tsai HJ, Chang JS, Li SS, Tang JL, Yeh SP, Hwang WL, Liu JH, Tan TD, Wang PN, Hsiao HH, Chen TY. 2018 Feb 12.
40. Investigation of treatment pattern, medical resource utilization and demographic prognostic factors in older patients with non-Hodgkin lymphoma: A nationwide population-based study. Cho SF, Wu WH, Yang YH, Liu YC, Hsiao HH, Chang CS. J Geriatr Oncol. 2018 Jul;9(4):315-320
41. Phe354Leu Polymorphism of LKB1 Is a Potential Prognostic Factor for Cytogenetically Normal Acute Myeloid Leukemia. Yang MY, Hsiao HH, Liu YC, Hsu CM, Lin SF, Lin PM. In vivo. 2017 Sep-Oct 31:841-847.
42. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, Pemmaraju N, Jabbour E, Bomalaski JS, Chen YP, Hsiao HH, Wang MC, Kuo CY, Chang H, Yeh SP, Cortes J, Chen LT, Chen TY. Sci Rep. 2017 Sep 12;7(1):11253.
43. IgG4-related disease with bone marrow involvement mimicking multiple myeloma. Tang SH, Lin MH, Du JS, Liu YC, Hsiao HH*, Liu TC. Br J Haematol. 2017 Jun;177(5):673.
44. Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma. Cho SF, Liu YC, Hsiao HH, Huang CT, Tsai YF, Wang HC, Lin SF, Liu TC. Sci Rep. 2017 Mar 14;7:44282. doi: 10.1038/srep44282.
45. Leukemic phase of CD5+ diffuse large B cell lymphoma. Hsiao HH, Wang HC, Tsai YF, Hsiao C, Cho SF, Liu YC, Lin SF, Liu TC. Turk J Haematol. 2017 Feb 9. doi: 10.4274/tjh.2016.0447
46. The epidemiologic transition of thalassemia and associated hemoglobinopathies in southern Taiwan. Wang HC, Hsieh LL, Liu YC, Hsiao HH, Lin SK, Tsai WC, Liu TC. Ann Hematol. 2016 Nov 28.
47. Discrepancy of ABO typing in acute leukemia patients. Ting SC, Sainamthip P, Hsiao HH*, Liu TC. Kaohsiung J Med Sci. 2016 Nov;32(11):595-596
48. Tuberculosis meningitis in patient with multiple myeloma during bortezomib-containing therapy. Tsai YC, Wang HC, Hsiao HH*, Liu TC. Kaohsiung J Med Sci. 2016 Oct;32(10):531-532.
49. Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia. Hsiao HH, Liu YC, Wang HC, Tsai YF, Wu CH, Cho SF, Hsu JF, Huang CT, Hsiao SY, Lee CP, Chang CS, Lin SF, Liu TC. Genet Mol Res. 2015 Dec 16;14(4):17028-33.
50. Up-regulation of PER3 Expression Is Correlated with Better Clinical Outcome in Acute Leukemia. Yang MY, Lin PM, Hsiao HH, Hsu JF, Lin HY, Hsu CM, Chen IY, Su SW, Liu YC, Lin SF. Anticancer Res. 2015 Dec;35(12):6615-22
51. Previous Exposure to Statin May Reduce the Risk of Subsequent Non-Hodgkin Lymphoma: A Nationwide Population-Based Case-Control Study. Cho SF, Yang YH, Liu YC, Hsiao HH, Huang CT, Wu CH, Tsai YF, Wang HC, Liu TC. PLoS One. 2015 Oct 1;10(10):e0139289.
52. Longitudinal risk of herpes zoster in patients with non-Hodgkin lymphpoma receiving chemotherapy: A nationwide population-based study. Cho SF, Wu WH, Yang YH, Liu YC, Hsiao HH, Chang CS. Sci Rep 2015:22:1400.
53. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma. Cho SF, Chang CS, Liu YC, Chang CS, Hsiao HH, Liu TC, Huang CT, Lin SF. Kaohsiung J Med Sci 2015: 31: 130-7.
54. Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoitic stem cell transplant. Wang HC, Liu YC, Tsai YF, Wu CH, Cho SF, Hsiao HH*, Lee GP, Lin SF, Liu TC. Ann Hematol 2015:94; 887-9.
55. The Potential of SIRT6 and SIRT7 as Circulating Markers for Head and Neck Squamous Cell Carcinoma. Lu CT, Hsu CM, Lin PM, Lai CC, Lin HC, Yang CH, Hsiao HH, Liu YC, Lin HY, Lin SF, Yang MY. Anticancer Res 2014:34;7137-43.
56. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. Cho SF, Chang YC, Chang CS, Lin SF, Liu YC, Hsiao HH, Chang JG, Liu TC. BMC Cancer 2014:14:809.
57. Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant. Hsiao HH, Liu YC, Wang HC, Wu CH, Cho SF, Hsu JF, Tsai HJ, Hsiao SY, Chang CS, Lin SF, Liu TC, Chuang WL, Yu ML. Transpl Infect Dis 2014:16:1003-6.
58. Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help. Monjazeb AM, Tietze JK, Grossenbacher SK, Hsiao HH, Zamora AE, Mirsoian A, Koehn B, Blazar BR, Weiss JM, Wiltrout RH, Sckisel GD, Murphy WJ. PLoS One 2014:13:e102709.
59. Therapeutic benefit of bortezomib on acute GVHD is tissue specific and is associated with IL-6 levels. Steven Pai CC, Hsiao HH, Sun K, Chen M, Hagino T, Tellez J, Mall C, Blazar BR, Monjazeb A, Abedi M, Murphy WJ. Biol Blood Marrow Transplant 2014:20:1899-904.
60. Mucosal lichen planus: an evidence-based treatment update. Davari P, Hsiao HH, Fazel N Am J Clin Dematol 2014;15: 181-195.
61. Deregulated expression of circadian clock genes in gastric cancer. Hu ML, Yeh KT, Lin PM, Hsu CM, Hsiao HH, Liu YC, Lin HY, Lin SF, Yang MY. BMC Gastroenterol 2014;14:67
62. Acute cerebral infarct with elevated factor VIII level during the thrombocytopenic stage after hematopoietic stem cell transplant. Hsiao HH, Huang HL, Wang HC, Tsai YF, Liu TC, Chang CS, Lin SF Exp Clin Transplant 2014;12:171-2.
63. Breakthrough Fusarium solani infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis. Wu CH, Lu PL, Hsiao HH, Liu TC, Lin SF, Chang CS, Hsu JF, Liu YC. Ann Hematol 2014;93:1079-1081.
64. Influenza infection results in local expansion of memory CD8(+) T cells with antigen non-specific phenotype and function. Sckisel GD, Tietze JK, Zamora AE, Hsiao HH, Priest SO, Wilkins DE, Lanier LL, Blazar BR, Baumgarth N, Murphy WJ. Clin Exp Immunol 2014;175:79-91.
65. Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients. Hsiao HH, Liu YC, Yang MY, Tsai YF, Liu TC, Chang CS, Lin SF. Genet Mol Res 2013; 12: 5617-5622.
66. Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. Liu YC, Hsiao HH, Lin PM, Yang WC, Chang CS, Liu TC, Hsu JF, Yang MY, Lin SF. Genet Mol Res 2013;12:5414-5423.
67. Trimethoprim/sulfamethoxazole-related acute psychosis in the second course of treatment after a stem cell transplant: case report and literature review. Hsiao HH, Chu NS, Tsai YF, Chang CS, Lin SF, Liu TC. Exp Clin Transplant 2013;11:467-468
68. Outcome of allotransplants in patients with chronic-phase chronic myeloid leukemia following imatinib failure: prognosis revisited. Liu YC, Hsiao HH, Chang CS, Liu TC, Yang WC, Hsu JF, Huang CT, Cho SF, Wu CH, Tsai YF, Lin SF. Anticancer Res 2013;33:4663-4667.
69. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. Bouchlaka MN, Sckisel GD, Chen M, Mirsoian A, Zamora AE, Maverakis E, Wilkins DE, Alderson KL, Hsiao HH, Weiss JM, Monjazeb AM, Hesdorffer C, Ferrucci L, Longo DL, Blazar BR, Wiltrout RH, Redelman D, Taub DD, Murphy WJ. J Exp Med 2013;210:2223-2237.
70. Sckisel GD, Tietze JK, Zamora AE, Hsiao HH, Priest SO, Wilkins DE, Lanier LL, Blazar BR, Baumgarth N, Murphy WJ. Influenza infection results in local expansion of memory CD8(+) T cells with antigen non-specific phenotype and function. Clin Exp Immunol 2014;175:79-91.
71. Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, Lin PM, Hsu JF, Lee CP, Lin SF. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: The association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib. Mol Carcinog 2013;
72. Lin HY, Lee SC, Lin SF, Hsiao HH, Liu YC, Yang WC, Hwang DY, Hung CC, Chen HC, Guh JY. Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels. Kaohsiung J Med Sci 2013;29:304-311.
73. Liu YC, Yang YH, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, Lin PM, Hsu JF, Chang PY, Lin SF. Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies - a nationwide population-based matched-control study in Taiwan. BMC Cancer 2012;12:503.
74. Sun K, Hsiao HH, Li M, Ames E, Bouchlaka M, Welniak LA, Hagino T, Pai CC, Chen M, Blazar BR, Abedi M, Murphy WJ. IFN-γ Receptor-Deficient Donor T Cells Mediate Protection from Graft-versus-Host Disease and Preserve Graft-versus-Tumor Responses after Allogeneic Bone Marrow Transplantation. J Immunol 2012.
75. Arta M Monjazeb, Hui-Hua Hsiao, Gail D. Sckisel, William J. Murphy. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. Journal of Immunotoxicology 2012.
76. Yang MY, Lin PM, Liu YC, Hsiao HH, Yang WC, Hsu JF, Hsu CM, Lin SF. Induction of cellular senescence by Doxorubicin is associated with upregulated miR-375 and induction of autophagy in K562 cells. PLoS One 2012;7:e37205
77. Hsiao HH, Liu YC, Lee CP, Chang CS, Lin SF. Philadelphia-negative chromosomal evolution during treatment for chronic myeloid leukemia. Genet Mol Res 2012;11:317-321.
78. Liu YC, Lu PL, Hsiao HH, Chang CS, Liu TC, Yang WC, Lin SF. Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2012;91:587-595.
79. Tietze JK, Sckisel GD, Hsiao HH, Murphy WJ. Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma. Int Rev Immunnol 2011;30:238-298.
80. Yang MY, Yang WC, Lin PM, Hsu JF, Hsiao HH, Liu YC, Tsai HJ, Chang CS, Lin SF. Altered expression of circadian clock genes in human chronic myeloid leukemia. J Biol Rhythms 2011;26:136-148.
81. Hsiao HH, Liu YC, Tsai HJ, Hsu JF, Yang WC, Chang CS, Lin SF. Additional chromosome abnormalities in chronic myeloid leukemia. Kaohsiung J Med Sci 2011;27:49-54.
82. Hsiao HH, Liu YC, Tsai HJ, Lee CP, Hsu JF, Lin SF. JAK2V617F mutation is associated with special alleles in essential thrombocythemia. Leuk Lymphoma 2011;52:478-482.
83. Hsiao HH, Tsai HJ, Liu YC, Lee CP, Lin SF. Allo-SCT in a rare t(8;21) evolution of CML. Bone Marrow Transplant 2010;45:1365-1366.
84. Kim DW, Goh YT, Hsiao HH, Caguioa PB, Kim D, Kim WS, Saikia T, Agrawal S, Roy A, Dai D, Bradley-Garelik MB, Mukhopadhyay J, Jootar S, Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. Int J Hematol 2009;89:664-672.
85. Hsiao HH, Yang SF, Liu YC, Yang MJ, Lin SF. Synchronous gastrointestinal stromal tumor and adenocarcinoma at the gastroesophageal junction. Kaohsiung J Med Sci 2009;25:338-341.
86. Hsiao HH, Liu YC, Hsu JF, Huang CF, Yang SF, Lin SF. Primary Liver Lymphoma with Hypercalcemia: A Case Report. Kaohsiung J Med Sci 2009;25:141-144.
87. Chiu HH, Tseng YT, Hsiao HP, Hsiao HH*. The AGG interruption pattern within the CGG repeat of the FMR1 gene among Taiwanese population. J Genet 2008;87:275-277.
88. Liu YC, Lu PL, Hsiao HH, Tsai HJ, Liu TC, Lin SF. Herpes Zoster infection associated with poor peripheral blood hematopoietic stem cell mobilization. J Formosa Med Asso 2008;107;958-960.
89. Hsiao HH, Yang WC, Liu YC, Lee CP, Lin SF. Disappearance of JAK2 V617F mutation in a rapid leukemic transformed essential thrombocythemia patient. Leuk Res. 2008;32:1323-1324.
90. Chiun Hsu, Chao A Hsiung, Ih-Jen Su, Wei-Shou Hwang, Ming-Chung Wang. Sheng-Fung Lin, Tseng-His Li, Hui-Hua Hsiao, Ji-Hsiiung Young, Ming-Chih Chang, Yu-Min Liao, Chi-Cheng Li, Hung-Bo Wu, Hwei-Fang Tien, Tsu-Yi Chao, Tsang-Wu Liu, Ann-Lii Cheng, Per-Jer Chen. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology 2008;47:844-853.
91. Hsiao HH, Liu YC, Hou MF, Lin SF. Uterine leiomyosarcoma metastasis to the breast. Eur J Gynaecol Oncol 2008;2:191-192.
92. Hsiao HH, Liu YC, Yang SF, LiN SF. A patient with concurrent gastrointestinal stromal tumor and Extramammary Paget’s disease. J Clin Gastroenterology 2008;42:1116.
93. Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC, Chang CS, Lin SF. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 2007; 35;1704-1707.
94. Hsiao HH, Lin SF. Pharmacogenetic syndrome of dihydropyrimidine dehydrogenase deficiency. Curr Pharmacogenomics 2007;5:31-38.
95. Liu YC, Hsiao HH, Chang JG, Yang MY, Liu TC, Chang CS, Tseng SB, Tsai HJ, Lin SF. Usefulness of Quantitative Assessment of JunB Gene Expression as a Marker for Monitoring Chronic Myeloid Leukemia Patients Undergoing Imatinib Therapy. Int J Hematol 2006; 84: 425-431.
96. Yang MY, Chang JG, Lin PM, Tang KP, Chen YH, Lin HY, Liu TC, Hsiao HH, Liu YC, Lin SF. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci 2006;12:1298-1307.
97. Hsiao HH, Liu YC, Tsai HJ, Chen LT, Lee CP, Chuan CH, Wang JY, Yang SF, Tseng YT, Lin SF. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute. Kaohsiung J Med Sci 2006; 22: 599-603.
98. Liu YC, Ito Y, Hsiao HH, Sashida G, Kodama A, Ohyashiki JH, Ohayshiki K. Risk facor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. Cancer Genet Cytogenet 2006; 171: 9-16.
99. Hsiao HH, Tsai HJ, Liu YC, Tseng YT, Tseng SB, Chai CY, Lin SF. A rare case of combined small-cell lung cancer with unusual soft tissue metastasis. Kaohsiung J Med Sci 2006; 22: 352-356.
100. Ishii Y, Hsiao HH, Sashida G, Ito Y, Miyazawa K, Kodama A, Ohyashiki JH, Ohyashiki K. Derivative (1;7)(q10;p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome. Cancer Genet Cytogenet 2006; 167: 131-137.
101. Hsiao HH, Tsai HJ, Liu YC, Tseng YT, Lu PL, Yang WC, Liu TC, Lin SF. Invasive fungal infections in patients with acute leukemia. Kaohsiung J Med Sci 2006; 22: 217-222.
102. Tseng YT, Hsiao HH, Hsiao HP, Tsai WC, Chiu HH. A study of PVRL1 mutations for non-syndromic cleft lip and/or palate among Taiwanese patients. Int J Oral Max Surg 2006; 35: 453-455.
103. Hsiao HH, Sashida G, Ito Y, Kodama A, Fukutake K, Ohyashiki JH, Ohyashiki K. Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10). Cancer Genet Cytogenet 2006;165:161-166.
104. Hsiao HH, Ito Y, Sashida G, Ohyashiki JH,Ohyashiki K. De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. Leuk Res. 2005;29(11):1247-52.
105. Hsiao HH, Liu YC, Tsai HJ, Tsai KB, Cheng YJ, Chou SH, Chong IW, Yang WC, Liu TC, Lin SF. Poor outcomes in patients with primary malignant mediastinal germ cell tumors. Kaohsiung J Med Sci 2005;21:561-565.
106. Hsiao HH, Sashida G, Ito Y, Tachino M, Beppu H, Ohyashiki K. Simultaneous occurrence of der(1;7)(q10;p10) and t(14;18)(q32;q21) in non-Hodgkin’s lymphoma: der(1;7) will appear as a secondary change in lymphoid neoplasia. Leuk Lymphoma 2005;46:949-950.
107. Hsiao HH, Sashida G, Kodama A, Fukutake K, Ohyashiki K. Variant translocation t(2;21;8) (q36;q22;q22) with RUNX1/CBFA2T1 (AML1/ETO) transcript in a case of acute myelogenous leukemia. Cancer Genet Cytogenet 2005;159:96-97.
108. Hsiao HH, Yang MY, Liu YC, Hsiao HP, Tseng SB, Chao MC, Liu TC, Lin SF. RBM15-MKL1 (OTT-MAL) fusion transcript in an adult acute myeloid leukemia patient. Am J Hematol 2005;79:43-45.
109. Lu PL, Hsiao HH, Tsai JJ, Chen TC, Feng MC, Chen TP, Lin SF. Dengue virus-associated hemophagocytic syndrome and dyserythropoiesis: a case report. Kaohsiung J Med Sci. 2005 Jan;21(1):34-39.
110. Hsiao HH, Ohyashiki K, Sashida G, Ito Y, Kodama A, Liu YC, Lin SF. Characteristics of myelodysplastic syndromes with der(1;7)(q10;p10): Report of 19 cases from Japan. Leuk Res 2005;29:s49.
111. Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, Chen TP, Lin SF. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemo Pharmacol 2004;53:445-451. (NSC 89-2314-B-037-103)
112. Hsiao HH, HungYH, Hsiao HP, Tseng SB, Tsai HJ, Liu YC, Liu TC, Chao MC, Yuli Chang, Lin SF. Case of chronic lymphocytic leukemia with unusual chromosomal aberrations. Int J Hematol 2004; 80: 351-353.
113. Tsai HJ, Lin SF, Liu TC, Chang CS, Hsiao HH, Chen TP. Pure red cell aplasia after ABO major-mismatched allogeneic peripheral blood stem cell transplantation successfully treated with plasma exchange and low-dose steroid: two case reports. Kaohsiung J Med Sci 2004;20:128-132.
114. Wang CH, Chen GS, Hsiao HH, Yang SF. Uterine leiomyosarcoma metastatic to the scalp- a case report and review of the literature. Dermatology Sinica 2004;22:69-73.
115. Tseng SB, Lin SF, Chang CS, Liu TC, Hsiao HH, Liu YC, Tsai HJ, Chen TP. Successful treatment of acquired pure red cell aplasia (PRCA) by allogeneic peripheral blood stem cell transplantation. Am J Hematol 2003; 74: 273-275.
116. Liu YC, Chang CS, Liu TC, Chen TP, Sue YC, Hsiao HH, Lin SF. Comparisons between allogeneic peripheral blood stem cell transplantation and allogeneic bone marrow transplantation in adult hematologic disease: a single center experience. Kaohsiung J Medl Sci 2003; 19: 541-548.
117. Hsiao HH, Liu TC, Chang CS, Su YC, Chen TP, Lin SF*. Secondary chronic myelogenous leukemia after autollogous peripheral blood stem cell transplantation for lymphoma. Int J Hematol 2001; 73:126-128.

Role: PI
1. A study of the molecular mechanisms by which NRF2 regulates PD-L1 expression and increases resistance to proteasome inhibitors in multiple myeloma cells.
2. Retrospective study of frequency about the antigens of red blood cells.
3. A Phase 3, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT- P10 and Rituxan in Patients with Low Tumor Burden Follicular Lymphoma.
4. Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients with Acute Myeloid Leukemia.
5. A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation.
6. A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission.
7. A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax CoAdministered with Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy.
8. A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation.
9. A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.
10. A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy.
11. A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study of Pracinostat in Combination with Azacitidine in Patients ≥18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy.
12. An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma.
13. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant.
14. A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide.
15. Screening gene mutations in myeloid cancers by next generation sequencing.
16. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
17. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation.
18. Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy.
19. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract.
20. A Randomized, Double-blind, Active-controlled, Phase 3 Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).
21. A Phase 1/2 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia.
22. A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Tumors or Non-Hodgkin’s Lymphoma.
23. A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia.
24. A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP).
25. A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia.
26. A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination with Ruxolitinib in Myeloproliferative Neoplasm Subjects.
27. A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis.

Role: Sub-I
1. A post-marketing, non-interventional, multi-center observational study to assess the safety and efficacy of Nilotinib in newly diagnosed patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase(CML-CP).
2. The Observational Registry: Nationwide Data Collection on Gastrointestinal Stromal Tumors (GISTs) Patients (Taiwan GISTs Registry).
3. Pharmacokinetic Study of Bortezomib(VELCADE®) Administered Intravenously in Taiwanese Patients with Multiple Myeloma – A Post Approval Commitment Study.
4. A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndromes (MDS).
5. A multicenter, phase 3, open-label, randomized study in relapsed/refractory patients with chronic lymphocytic leukemia to evaluate the benefit of GDC-0199(ABT-199) plus Rituximab compared with Bendamustine plus Rituximab.
6. A randomized, multicenter, open-label, phase 3 study of the Bruton’s Kinase(BTK) inhibitor PCI-32765(Ibrutinib) versus Rituximab in subjects with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
7. A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.
8. Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor (EGFRTKI).
9. A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
10. A Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β)-thalassemia.
11. A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Bio-marker of OPB-111077 in Subjects with Advanced Cancer.
12. A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT‑MM study.
13. Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and cisplatin (GC)in locally advanced or metastatic biliary tract cancer.
14. The Effects of Platelet-Rich Plasma (PRP) on the Function of Female Urethra and Vagina.
15. A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma.
16. Posaconazole prophylaxis compared with other antifungal agents in patients with myelodysplastic syndrome or acute myelogenous leukemia receiving induction chemotherapy and in patients with hematological malignancies receiving allogeneic hematopoietic stem cell transplantation.
17. The study of medical resource utilization and clinical outcome in Patient with multiple myeloma.
18. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled trial comparing the efficacy and safety of Polatuzumab Vedotin in combination with Rituximab and CHP (R-CHP) versus Rituximab and CHOP (R-CHOP) in previously untreated patients with diffuse large B-cell lymphoma.
19. A Multicenter, Double-Blind, Randomized, Placebo controlled study of Varlitinib plus Capecitabine versus placebo plus Capecitabine in patients with advanced or metastatic biliary tract cancer as second-line systemic therapy.
20. Phase II Trial of Biweekly S-1, Leucovorin and Gemcitabine (GSL) in Elderly Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma.
21. Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and cisplatin (GC)in locally advanced or metastatic biliary tract cancer.
22. A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion.
23. A Phase II Randomized Study of SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Unresectable or Metastatic Pancreatic Cancer.
24. The immunoprofiling of lymphocytosis and the quantitative and functional analysis of natural killer cells in chronic phase-chronic myeloid leukemia patients treated with dasatinib.